tbuckley/cabot-search huggingface dataset:
PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition
Authors: Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, Dan Xie
Journal: Clinical Cancer Research (2018)

Circular RNAs (circRNAs), a novel class of noncoding RNAs, have recently drawn lots of attention in the pathogenesis of human cancers. However, the role of circRNAs in cancer cells epithelial-mesenchymal transition (EMT) remains unclear. In this study, we aimed to identify novel circRNAs that regulate urothelial carcinoma of the bladder (UCB) cells' EMT and explored their regulatory mechanisms and clinical significance in UCBs.We first screened circRNA expression profiles using a circRNA microarray in paired UCB and normal tissues, and then studied the clinical significance of an upregulated circRNA, circPRMT5, in a large cohort of patients with UCB. We further investigated the functions and underlying mechanisms of circPRMT5 in UCB cells' EMT. Moreover, we evaluated the regulation effect of circPRMT5 on miR-30c, and its target genes, SNAIL1 and E-cadherin, in two independent cohorts from our institute and The Cancer Genome Atlas (TCGA).We demonstrated that upregulated expression of circPRMT5 was positively associated with advanced clinical stage and worse survival in patients with UCB. We further revealed that circPRMT5 promoted UCB cell's EMT via sponging miR-30c. Clinical analysis from two independent UCB cohorts showed that the circPRMT5/miR-30c/SNAIL1/E-cadherin pathway was essential in supporting UCB progression. Importantly, we identified that circPRMT5 was upregulated in serum and urine exosomes from patients with UCB, and significantly correlated with tumor metastasis.CircPRMT5 exerts critical roles in promoting UCB cells' EMT and/or aggressiveness and is a prognostic biomarker of the disease, suggesting that circPRMT5 may serve as an exploitable therapeutic target for patients with UCB.
Analysis of a Commercial Insurance Policy to Deny Coverage for Emergency Department Visits With Nonemergent Diagnoses
Authors: Shih-Chuan Chou, Suhas Gondi, Olesya Baker, Arjun K. Venkatesh, Jeremiah D. Schuur
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Insurers have increasingly adopted policies to reduce emergency department (ED) visits that they consider unnecessary. One common approach is to retrospectively deny coverage if the ED discharge diagnosis is determined by the insurer to be nonemergent. <h3>Objective</h3> To characterize ED visits that may be denied coverage if the ED coverage denial policy of a large national insurer, Anthem, Inc, is widely adopted. <h3>Design, Setting, and Participants</h3> A cross-sectional analysis of probability-sampled ED visits from the nationally representative National Hospital Ambulatory Medical Care Survey ED subsample occurring from January 1, 2011, to December 31, 2015, was conducted. Visits by commercially insured patients aged 15 to 64 years were examined. Those with ED discharge diagnoses defined by Anthem's policy as nonemergent and therefore subject to possible denial of coverage were classified as denial diagnosis visits. The primary presenting symptoms among denial diagnosis visits were identified, and all visits by commercially insured adults presenting with these primary symptoms were classified as denial symptom visits. <h3>Main Outcomes and Measures</h3> Each visit cohort as a weighted proportion of commercially insured adult ED visits. The proportion of each visit cohort that received ED-level care, defined as visits where patients were triaged as urgent or emergent, received 2 or more diagnostic tests, or were admitted or transferred, was also examined. <h3>Results</h3> From 2011 to 2015, 15.7% (95% CI, 15.0%-16.4%) of commercially insured adult ED visits (4440 of 28 304) were denial diagnosis visits (mean [SD] patient age, 36.6 [14.0] years; 2592 [58.7%] female and 2962 [63.5%] white). Among these visits, 39.7% (95% CI, 37.1%-42.3%) received ED-level care: 24.5% (95% CI, 21.7%-27.4%) were initially triaged as urgent or emergent and 26.0% (95% CI, 23.8%-28.3%) received 2 or more diagnostic tests. These denial diagnosis visits shared the same presenting symptoms as 87.9% (95% CI, 87.3%-88.4%) of commercially insured adult ED visits (24 882 of 28 304) (mean [SD] patient age, 38.5 [14.1] years; 14 362 [57.9%] female and 17 483 [68.7%] white). Among these denial symptom visits, 65.1% (95% CI, 63.4%-66.9%) received ED-level care: 43.2% (95% CI, 40.2%-46.4%) were triaged as urgent or emergent, 51.9% (95% CI, 50.0%-53.9%) received 2 or more diagnostic tests, and 9.7% (95% CI, 8.8%-10.6%) were admitted or transferred. <h3>Conclusions and Relevance</h3> Anthem's nonemergent ED discharge diagnoses were not associated with identification of unnecessary ED visits when assessed from the patient's perspective. This cost-reduction policy could place many patients who reasonably seek ED care at risk of coverage denial.
VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors
Authors: S.F. Powell, M.R. Patel, J. Merchan, J. Strauss, T.P. Cripe, M.O. Old, R.M. Diaz, M. Reckner, B. Brunton, N. Packiriswamy, D. Upreti, L. Suksanpaisan, R. Vandergaast, R. Khan, S.J. Russell, K.W. Peng, A.S. Bexon
Journal: Annals of Oncology (2018)
Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
Authors: E Antonio Chiocca, Farshad Nassiri, Justin Wang, Pierpaolo Peruzzi, Gelareh Zadeh
Journal: Neuro-Oncology (2018)

A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These replication-competent (tumor-selective, oncolytic, replication-conditional) viruses or replication-defective viral vectors (gene therapy) deliver cytotoxic payloads to tumors, leading to immunogenic death and intratumoral inflammatory responses. This transforms the tumor microenvironment from immunologically naïve ("cold") to inflamed ("hot"), increasing immune cell recognition of tumor antigens and the durable responses observed in virotherapy.3,4 Several current and past virotherapy trials have reported a "tail" of apparent responders at the 24-month landmark. Other modalities have also reported a "tail" of seemingly long-term survivors. These trials seem to show that these responder "tails" characterize a defined subset of GBM patients.
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns
Authors: Daniela Loessner, Anja Rockstroh, Ali Shokoohmand, Boris M. Holzapfel, Ferdinand Wagner, Jeremy Baldwin, Melanie Boxberg, Barbara Schmalfeldt, Ernst Lengyel, Judith A. Clements, Dietmar W. Hutmacher
Journal: Biomaterials (2018)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Authors: Maura C. O'Leary, Xiaobin Lu, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiowjen Lee, Ke Liu, Bindu George, Wilson Bryan, Marc R. Theoret, Richard Pazdur
Journal: Clinical Cancer Research (2018)

Abstract Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory in second or later relapse. Approval was based on the complete remission (CR) rate, durability of CR, and minimal residual disease (MRD) &amp;lt;0.01% in a cohort of 63 children and young adults with relapsed or refractory ALL treated on a single-arm trial (CCTL019B2202). Treatment consisted of fludarabine and cyclophosphamide followed 2 to 14 days later by a single dose of tisagenlecleucel. The CR rate was 63% (95% confidence interval, 50%–75%), and all CRs had MRD &amp;lt;0.01%. With a median follow-up of 4.8 months, the median duration of response was not reached. Cytokine release syndrome (79%) and neurologic events (65%) were serious toxicities reported in the trial. With implementation of a Risk Evaluation and Mitigation Strategy, the benefit–risk profile was considered acceptable for this patient population with such resistant ALL. A study of safety with 15 years of follow-up is required as a condition of the approval. See related commentary by Geyer, p. 1133
Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors
Authors: B.C. Cho, R. Perets, J. Bar, M.-J. Ahn, D.-W. Kim, K. Yoh, A. Nagrial, D.R. Spigel, D.H. Lee, M. Gutierrez, D. Kotasek, S. Siddiqi, A. Chain, B.D. Butts, Y. Zhang, X. Li, J. Cyrus, A. Tse, R.A. Altura, D. Rasco
Journal: Annals of Oncology (2018)
Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers
Authors: Kaicheng Li, Xiao Luo, Qingze Zeng, Yeerfan Jiaerken, Xiaojun Xu, Peiyu Huang, Zhujing Shen, Jingjing Xu, Chao Wang, Jiong Zhou, Min-Ming Zhang
Journal: Translational Neurodegeneration (2018)

Individuals with subjective memory complaints (SMC) feature a higher risk of cognitive decline and clinical progression of Alzheimer's disease (AD). However, the pathological mechanism underlying SMC remains unclear. We aimed to assess the intrinsic connectivity network and its relationship with AD-related pathologies in SMC individuals.We included 44 SMC individuals and 40 normal controls who underwent both resting-state functional MRI and positron emission tomography (PET). Based on graph theory approaches, we detected local and global functional connectivity across the whole brain by using degree centrality (DC) and eigenvector centrality (EC) respectively. Additionally, we analyzed amyloid deposition and tauopathy via florbetapir-PET imaging and cerebrospinal fluid (CSF) data. The voxel-wise two-sample T-test analysis was used to examine between-group differences in the intrinsic functional network and cerebral amyloid deposition. Then, we correlated these network metrics with pathological results.The SMC individuals showed higher DC in the bilateral hippocampus (HP) and left fusiform gyrus and lower DC in the inferior parietal region than controls. Across all subjects, the DC of the bilateral HP and left fusiform gyrus was positively associated with total tau and phosphorylated tau181. However, no significant between-group difference existed in EC and cerebral amyloid deposition.We found impaired local, but not global, intrinsic connectivity networks in SMC individuals. Given the relationships between DC value and tau level, we hypothesized that functional changes in SMC individuals might relate to pathological biomarkers.
Modification of cellular and humoral immunity by somatically reverted T cells in X-linked lymphoproliferative syndrome type 1
Authors: Akihiro Hoshino, Xi Yang, Kay Tanita, Kenichi Yoshida, Toshiaki Ono, Naonori Nishida, Yusuke Okuno, Takeyuki Kanzaki, Kumiko Goi, Hisanori Fujino, Koichi Ohshima, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Seiji Kojima, Tomohiro Morio, Hirokazu Kanegane
Journal: Journal of Allergy and Clinical Immunology (2018)
What is early COPD and why is it important?
Authors: Joan B. Soriano, Francesca Polverino, Borja G. Cosio
Journal: European Respiratory Journal (2018)

There is increasing interest in the origins of chronic obstructive pulmonary disease (COPD), as it is envisaged that preventive efforts and treatment can modify its clinical course. The concept of early COPD is not new, but it has recently regained interest, given new population data, recent cellular and molecular advances and insights from clinical trials. To date, many knowledge gaps in the nature of early COPD still exist, mainly because COPD has always been considered a disease of the elderly, and little attention has been paid to the pathological changes occurring in the lungs of individuals at risk before they develop clinically evident COPD. Future studies should focus on identifying early pathological manifestations of COPD in order to prevent its progression in susceptible individuals. In this review, we aim to summarise what is known on early COPD, from the epidemiological, cellular and clinical perspectives.
P3.16-48 Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?
Authors: O. Alan, O. Ercelep, T. Akin Telli, T. Basoglu Tuylu, T. Önes, E. Bozkurtlar, N. Akgül Babacan, T. Lacin, B. Yıldızeli, H. Batirel, S. Kaya, F. Dane, P. Yumuk
Journal: Journal of Thoracic Oncology (2018)
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial
Authors: F. Bozorgmehr, A. Hommertgen, F. Lasitschka, J. Krisam, J. Debus, J.R. Fischer, M. Bischof, A. Atmaca, S. Wetzel, M. Faehling, D. Bottke, C. Grohe, W. Engel-Riedel, E. Ingenhoff, D.F. Heigener, N. Reinmuth, C. Schumann, M. Wermke, M. Thomas, S. Rieken
Journal: Annals of Oncology (2018)
Avoiding Topical Agents Before Daily Radiotherapy
Authors: Simon A. Brown, Chelsea C. Pinnix
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
GW29-e1825 Listening to the story of life and illness: preliminary findings from a qualitative study on the experiences and decision-making considerations of post-PCI patients
Authors: Peng Tian, Tao Wang, Jianzhong Pang, Jie Li, Yafang Deng, Dengfeng Kong, Wei Mu, Baohe Wang
Journal: Journal of the American College of Cardiology (2018)
Abstract 01: The Impact of School Food Environment Policies on Child Dietary Intake and BMI and Future Cardiometabolic Outcomes in the United States
Authors: Katherine L Rosettie, Renata Micha, Jose L Peñalvo, Frederick Cudhea, Dariush Mozaffarian
Journal: Circulation (2017)

Introduction: Promising school food environment policies include providing fresh fruits and vegetables (F&amp;V provision) and competitive food restrictions on sugar-sweetened beverages (SSB restriction). Yet, the impact of these policies on diet and BMI in children and future cardiometabolic disease (CMD) outcomes is not established. Methods: We used a comparative risk assessment model to estimate the effects of F&amp;V provision and SSB restriction on diet and BMI in US children age 5-18 yrs. We used national data from NHANES 2009-12 on baseline BMI and intakes of fruits, vegetables, and SSBs; impacts of these policies on diet from meta-analyses of interventions; and estimated effects of dietary changes on BMI from trials and cohorts. We also estimated the effects of these school policies on CMD in current US adults if such policies had been implemented in their childhood, based on meta-analysis of long-term within-person correlations of childhood and adult diets, meta-analyses of diet and CMD, and data on national CMD deaths. Model inputs were stratified by age, sex, and race, where appropriate. Point estimates and 95% uncertainty intervals were derived from probabilistic sensitivity analyses using 1000 Monte Carlo simulations. Results: F&amp;V provision would increase overall fruit intake in children by ~ 14-21% and would not significantly increase vegetable intake ( Table ). SSB restriction would decrease overall SSB intake by ~ 6-11% and BMI (kg/m 2 ) by 0.2-0.3%. Among these dietary factors, reducing SSBs had the largest estimated impact on CMD (2418 deaths averted/year), followed by providing fruits (2121) and vegetables (165). If US adults had been exposed to both policies, an estimated 4703 CMD deaths/year would be averted, representing 0.67% of all CMD deaths. Conclusions: Specific US school food environment policies involving F&amp;V provision and SSB restriction would modestly improve diet and BMI in children, and could prevent up to 0.7% of all CMD deaths.
Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant
Authors: Sarah Beaussant Cohen, Wayne Bainter, Jared L. Johnson, Ting-Yu Lin, Jenny C.Y. Wong, Jacqueline G. Wallace, Jennifer Jones, Sonia Qureshi, Fatima Mir, Farah Qamar, Lewis C. Cantley, Raif S. Geha, Janet Chou
Journal: Journal of Allergy and Clinical Immunology (2018)
Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy
Authors: J.H. Lee, S.Y. Lim, A.M. Menzies, M.S. Carlino, A. Guminski, K. Nahar, D. Palmieri, E. Breen, R. Kefford, R. Scolyer, G.V. Long, H. Rizos
Journal: Annals of Oncology (2018)
Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events
Authors: None Simonaggio, J.-M. Michot, S. Champiat, A. Vozy, A. Lapera, A. Marabelle, J. Le Pavec, A.-L. Voisin, A. Lallart, G. Cengizalp, O. Lambotte
Journal: Annals of Oncology (2018)
IL-5 Levels in Nasosorption and Sputosorption Correlate with Sputum Eosinophilia in Allergic Asthma
Authors: Jose T. Melo, Tanushree Tunstall, Marcia M. M. Pizzichini, Rosemeri Maurici, Cristiane C. Rocha, Felipe Dal-Pizzol, Jessica Gonçalves, Trevor T. Hansel, Ryan S. Thwaites, Emilio Pizzichini
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients
Authors: Marion Delcroix, Gerd Staehler, Henning Gall, Ekkehard Grünig, Matthias Held, Michael Halank, Hans Klose, Anton Vonk-Noordegraaf, Stephan Rosenkranz, Joanna Pepke-Zaba, Christian F. Opitz, J. Simon R. Gibbs, Tobias J. Lange, Iraklis Tsangaris, Doerte Huscher, David Pittrow, Karen M. Olsson, Marius M. Hoeper
Journal: European Respiratory Journal (2018)

Abbreviated versions of the risk stratification strategy of the European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines have been recently validated in patients with pulmonary arterial hypertension. We aimed to investigate their prognostic value in medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients from the COMPERA registry, which collects six variables of interest (World Health Organization Functional Class, 6-min walk distance, brain natriuretic peptide, right atrial pressure, cardiac index and mixed venous oxygen saturation). We included patients with at least one follow-up visit, no pulmonary endarterectomy and at least three of the six variables available, and classified the patients into low-, intermediate- and high-risk groups. As a secondary analysis, the number of noninvasive low-risk criteria was counted. The association between risk assessment and survival was evaluated. Data from inclusion and follow-up (median 7 months) visits were available for 561 and 231 patients, respectively. Baseline 1- and 5-year survival estimates were significantly different (p&lt;0.0001) in the baseline low-risk (98.6% and 88.3%, respectively), intermediate-risk (94.9% and 61.8%, respectively) and high-risk (75.5% and 32.9%, respectively) cohorts. Follow-up data were even more discriminative, with 100%, 92% and 69% 1-year survival, respectively. The number of low-risk noninvasive criteria was also associated with survival. These analyses suggest that the ESC/ERS risk assessment may be applicable in patients with medically treated CTEPH.
Colorectal Cancer Control
Authors: Beverly B. Green
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Authors: C. Hall, K.R. Hess, L. Ravenberg, A. Clayborn, G.M. Rauch, R. Candelaria, E.A. Mittendorf, S.L. Moulder, A. Thompson, A. Lucci
Journal: Annals of Oncology (2018)
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models
Authors: A. Gkountakos, S. Pilotto, M. Simbolo, C. Vicentini, A. Mafficini, A. del Curatolo, A. Scarpa, G. Tortora, V. Corbo, E. Bria
Journal: Annals of Oncology (2018)